Exploring novel isatin derivatives as SARS-CoV-2 3CL(pro) inhibitors.

Song J, Shi C, Yang B, Yang J, Huang C, Liu J, Wu S, Mo S, Yang J

Open source

DOI
10.1080/14756366.2026.2707859
Published
2026 Dec
Container
Journal of enzyme inhibition and medicinal chemistry
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14756366.2026.2707859,
  title = {Exploring novel isatin derivatives as SARS-CoV-2 3CL(pro) inhibitors.},
  author = {Song J and Shi C and Yang B and Yang J and Huang C and Liu J and Wu S and Mo S and Yang J},
  year = {2026},
  journal = {Journal of enzyme inhibition and medicinal chemistry},
  doi = {10.1080/14756366.2026.2707859},
  url = {https://doi.org/10.1080/14756366.2026.2707859}
}

RIS

TY  - JOUR
TI  - Exploring novel isatin derivatives as SARS-CoV-2 3CL(pro) inhibitors.
AU  - Song J
AU  - Shi C
AU  - Yang B
AU  - Yang J
AU  - Huang C
AU  - Liu J
AU  - Wu S
AU  - Mo S
AU  - Yang J
PY  - 2026
JO  - Journal of enzyme inhibition and medicinal chemistry
DO  - 10.1080/14756366.2026.2707859
UR  - https://doi.org/10.1080/14756366.2026.2707859
ER  - 

APA

J, S., C, S., B, Y., J, Y., C, H., J, L., S, W., S, M., & J, Y. (2026). Exploring novel isatin derivatives as SARS-CoV-2 3CL(pro) inhibitors.. Journal of enzyme inhibition and medicinal chemistry. https://doi.org/10.1080/14756366.2026.2707859

Source records